Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Eisai Limited
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
A Double-blind, Placebo-controlled, Dose-escalation, Parallel Group Study of E2007 given as Adjunctive Therapy in Patients with Refractory Partial Seizures
- To determine the maximal tolerated dose (MTD) of E2007 when added to concomitant antiepileptic drugs (AEDs), given bid or qd to patients with refractory partial onset seizures (including secondarily...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
A research study to assess whether lorcaserin HCl affects the risk of developing cardiovascular diseases in obese or overweight men and women at higher risk of developing these diseases
-To demonstrate that, in obese and overweight subjects with cardiovascular (CV) disease and/or multiple CV risk factors, lorcaserin HCl 10 mg administered twice daily (BID) does not increase the incid...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
A Multi-Center, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 (Perampanel) in Patients with Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)
The primary objective is to evaluate long-term (1-year) safety while administering perampanel to patients with PDN or PHN.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children with Attention Impairment Following Cancer Treatment
To evaluate the efficacy of donepezil in children with attention impairment that is present at least 12 months after the completion of cancer treatment
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
A 14-Month Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 as an Adjunctive Therapy in Patients With Refractory Partial Seizures (revised per Amendments 02 and 03)
The primary objective for this study is to evaluate the safety of E2007 given as adjunctive, long-term treatment in patients with refractory partial onset seizures with or without secondary generaliza...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
A Phase III Open Label, Randomized Parallel Two-Arm Multi Center Study of E7389 versus ‘Treatment of Physician’s Choice’ in Patients with Locally Recurrent or Metastatic Breast Cancer, Previously Treated with At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane
To compare the overall survival (OS) of patients treated with E7389 versus the Treatment of Physician’s Choice (including anti-tumor treatment of the investigator’s choice and palliative treatment) in...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
A double-blind, randomised, placebo-controlled, multicentre study to assess the efficacy and safety of adjunctive zonisamide in primary generalised tonic clonic seizures
The objective of this study is to assess the efficacy of adjunctive zonisamide in idiopathic generalised epilepsy (IGE) in reducing the frequency of tonic-clonic seizures in subjects with continuing p...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects with Psoriasis Vulgaris
To demonstrate that at least one concentration of topical E6201 gel has superior efficacy compared with vehicle on the reduction of psoriatic infiltrate thickness during 12 Days of treatment in subjec...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Commercially Available Therapies
To provide eribulin to patients with advanced breast cancer who have no further treatment options and therapy is requested by an investigator
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eisai Limited
MAJ Il y a 5 ans
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Explore the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients with Refractory Partial Seizures
The primary objective is to determine the tolerability of doses up to a maximum of 12 mg per day of E2007 in patients with refractory partial seizures who are taking inducing and noninducing anti-epil...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
Suivant